Clinical Outcomes of COVID-19 Patients with Pre-existing, Compromised Immune Systems: A Review of Case Reports
| Autor: | Tanner Corse, Sydney Kersten, Fortunato Battaglia, Stanley R Terlecky, Zhiyong Han, Linda Dayan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) Primary Immunodeficiency Diseases Pneumonia Viral MEDLINE Comorbidity Review Organ transplantation Virus Betacoronavirus Immunocompromised Host Immune system Pandemic medicine Humans Mortality Intensive care medicine Pandemics business.industry SARS-CoV-2 COVID-19 General Medicine medicine.disease Prognosis Transplant Recipients Immune System Diseases Pre-existing business Coronavirus Infections Immunosuppressive Agents |
| Zdroj: | International Journal of Medical Sciences |
| ISSN: | 1449-1907 |
| Popis: | In the ongoing COVID-19 pandemic, all COVID-19 patients are naive patients as it is the first-time humans have been exposed to the SARS-CoV-2 virus. As with exposure to many viruses, individuals with pre-existing, compromised immune systems may be at increased risk of developing severe symptoms and/or dying because of (SARS-CoV-2) infection. To learn more about such individuals, we conducted a search and review of published reports on the clinical characteristics and outcomes of COVID-19 patients with pre-existing, compromised immune systems. Here we present our review of patients who possess pre-existing primary antibody deficiency (PAD) and those who are organ transplant recipients on maintenance immunosuppressants. Our review indicates different clinical outcomes for the patients with pre-existing PAD, depending on the underlying causes. For organ transplant recipients, drug-induced immune suppression alone does not appear to enhance COVID-19 mortality risk - rather, advanced age, comorbidities, and the development of secondary complications appears required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|